Why the MGC Pharmaceuticals (ASX:MXC) share price is jumping 8%

The MGC Pharmaceuticals (ASX:MXC) share price is surging after the company's drug was passed by two ethics committees. Here's the lowdown.

| More on:
Young doctor raising arms in air with hands in fists celebrating a new development

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

MGC Pharmaceuticals (ASX: MXC) shares are on the rise today after the company advised two ethics committees have passed its product for phase III clinical trials on COVID-19 patients. At the time of writing, the MGC Pharmaceuticals share price has surged 8% to 8.1 cents.

The pharmaceutical company's CimatrA is designed to target infections with inflammatory complications and has been passed for trials at two separate hospitals.

Let's look take a closer look at the company's news.

Phase III clinical trials

The MGC Pharmaceuticals share price is gaining ground today after the company stated its CimetrA™ product has been approved by two ethics committees. The trials will evaluate the drug's efficacy to treat hospitalised patients diagnosed with moderate COVID-19. It will also provide further data on the use of CimetrA as an investigational medicinal product (IMP).

The trials will take place in Israel, at the Rambam Health Care Campus and Nazareth Hospital EMMS. They are expected to begin next month and be completed by September. Full results are expected to be available in October 2021.

CimetrA has had a name change due to the trial. It was formerly known as ArtemiC™, a name which will live on as a food supplement.

The company states that CimetrA encapsulates technology that delivers active ingredients more effectively in higher concentrations, improving the bioavailability of natural active ingredients.

Commentary from management

Co-founder and managing director of MGC Pharmaceuticals Roby Zomer commented on the ethics committee's approval of CimatrA's stage III trial:

This is a very significant milestone for the Company being the first Phase III clinical trial of CimetrA™. ArtemiC™ has already proven to be a very successful product for the Company, and we look forward to replicating this with CimetrA as an IMP and improve outcomes for COVID-19 patients.

MGC Pharmaceuticals share price snapshot

The MGC Pharmaceuticals share price is having a fantastic year. Currently, the company's shares are up by 350% year to date.

MGC Pharmaceuticals has a market capitalisation of around $170 million, with approximately 2.2 billion shares outstanding.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Unsure man analysing data on laptop.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a disappointing end to a disappointing week for investors this Friday.

Read more »

Six smiling office colleagues stand in a row and look at the camera.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
Share Fallers

Why ANZ, Clarity, IGO, and Pilbara Minerals shares are dropping today

These shares are ending the week in the red. But why?

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Share Gainers

Why Betr, Centuria Capital, GR Engineering, and Mach7 shares are pushing higher

These shares are having a good finish to the week. But why?

Read more »

woman holding 'hiring' sign in shop
Broker Notes

How much upside does Macquarie tip for Seek shares?

The broker recently reviewed Australian job ad volumes for May.

Read more »

Ecstatic woman looking at her phone outside with her fist pumped.
Broker Notes

Macquarie tips 50% return for this cheap ASX All Ords stock

Let's see which stock the broker is feeling bullish about this week.

Read more »

A woman sits at her home computer with baby on her lap, and the winning ticket in her hand.
Consumer Staples & Discretionary Shares

How much upside does Macquarie expect for Lottery Corporation shares?

This ASX 200 stock has proven resilient through various economic conditions.

Read more »

ASX 200 retail shares a woman smiles over the top of multiple shopping bags she is holding in both hands up near her face.
Opinions

Up 90% in a year, is it too late to buy Zip shares?

Should investors buy this stock now or wait until later?

Read more »